Pliant Therapeutics
PLRX
99 hedge funds and large institutions have $74.7M invested in Pliant Therapeutics in 2025 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 42 reducing their positions, and 26 closing their positions.
25% more capital invested
Capital invested by funds: $59.7M → $74.7M (+$14.9M)
1.77% less ownership
Funds ownership: 83.88% → 82.11% (-1.8%)
13% less funds holding
Funds holding: 114 → 99 (-15)
34% less call options, than puts
Call options by funds: $107K | Put options by funds: $161K
48% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 42
54% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 26
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.62M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$3.29M |
| 3 |
EP
Eversept Partners
New York
|
+$1.26M |
| 4 |
Renaissance Technologies
New York
|
+$1.24M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$4.58M |
| 2 |
MAP
Madison Avenue Partners
New York
|
-$2.59M |
| 3 |
TGI
TRV GP IV
Boston,
Massachusetts
|
-$2.47M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.02M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$1.25M |
PLRX Hedge Fund Activity: Q3 2025 in Review
99 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q3 2025, worth a combined $74.7M — up 25% from $59.7M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of PLRX and 12 opened new positions — a net loss of 14 holders — while 42 trimmed existing stakes and 22 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $6.62M. The largest seller was Deep Track Capital, exiting entirely with an estimated $4.58M sold.
- 99 institutional investors held Pliant Therapeutics (PLRX) as of Q3 2025, down from 114 in Q2 2025.
- Funds reported $74.7M of Pliant Therapeutics stock for Q3 2025, up 25% quarter-over-quarter.
- 12 funds opened new Pliant Therapeutics positions in Q3 2025 and 26 closed out, a net change of -14 holders.
- The largest Pliant Therapeutics buyer in Q3 2025 was Point72 Asset Management, an estimated $6.62M added.
- The largest Pliant Therapeutics seller in Q3 2025 was Deep Track Capital, an estimated $4.58M sold.
Based on aggregated 13F filings for Q3 2025.